Denosumab Reaches a Difficult Multiple Myeloma Population, But Calcium Control Becomes the Price of Entry
In multiple myeloma, bone destruction and kidney failure often travel together, and that overlap has long complicated supportive care. Bisphosphonates remain effective bone-modifying agents, but their renal toxicity narrows their use when creatinine clearance falls below 30 mL/min. Denosumab avoids direct nephrotoxicity and has already earned a place in myeloma bone care, yet the pivotal randomized trial excluded the very patients most likely to need an alternative. This multicenter phase 2 study set out to answer a clinically stubborn question: can denosumab still suppress bone resorption in patients with severe renal impairment, and at what cost?
The answer was biologically convincing and clinically uncomfortable.
Investigators enrolled adults with newly diagnosed or relapsed myeloma and creatinine clearance below 30 mL/min, including a substantial dialysis population. Twenty-four patients were enrolled across six sites, and 22 received denosumab and entered the analysis. Median age was 68 years, 55% had newly diagnosed disease, median creatinine clearance was 23.8 mL/min, and 41% were on dialysis. Participants received open-label denosumab 120 mg subcutaneously every four weeks for 12 cycles, with calcium and vitamin D supplementation mandated before treatment began. The primary endpoint was change in serum C-terminal telopeptide of type I collagen, or CTX, at three months.
Bone Resorption Fell Sharply Despite Advanced Kidney Disease
CTX fell decisively. Median serum CTX dropped from 864 pg/mL at baseline to 292 pg/mL at 3 months, a 73% median reduction among 18 evaluable patients. For a biomarker that tracks osteoclast activity, this is the signal clinicians want to see: RANKL blockade is still doing its job even when kidney function is profoundly compromised. In myeloma, where malignant plasma cells and osteoclast activation reinforce one another, suppressing resorption is more than a laboratory exercise. It is the pharmacologic logic behind preventing fractures, vertebral collapse, and the cascade of pain and immobility that follows skeletal injury.
Skeletal-related events still occurred, and they arrived early in some patients. Three events were documented: an L5 compression fracture at 1 month in relapsed disease, an L1 compression fracture at 5.5 months in relapsed disease, and rib fractures at 5.8 months in newly diagnosed disease. One-year skeletal-related event-free survival was 85.4%, with a 95% confidence interval of 71.4% to 100%. The cohort is small, but the event rate is not trivial. Myeloma bone disease remains active enough that even a potent antiresorptive agent cannot erase every fracture risk, especially when disease biology is aggressive or treatment is interrupted.
Hypocalcemia Emerged as the Dominant Safety Problem
The safety profile was dominated by hypocalcemia. Any-grade hypocalcemia affected 77.3% of patients, and grade 3 or higher hypocalcemia occurred in 31.8%. Four patients required intravenous calcium, including two patients receiving dialysis. Calcitriol was used in seven patients. Denosumab was held in 12 patients, most often because of hypocalcemia. Every patient with a hypocalcemia-related hold resumed treatment at the same schedule without dose reduction after a mean interruption of 64 ± 14 days.
This is where the biology turns sharp. Denosumab blocks osteoclast-mediated calcium release from bone, and patients with advanced kidney disease have less physiologic reserve to buffer that drop. Dialysis patients showed a trend toward more grade 2 or higher hypocalcemia than those not on dialysis, 77.8% versus 38.5%, with an odds ratio of 5.1. Baseline CTX was strongly and inversely correlated with the lowest calcium during treatment, suggesting that patients with more active bone turnover were also more vulnerable to the calcium shift caused by RANKL inhibition. In practical terms, the patients with the most dynamic skeletal disease may also be the ones most likely to fall hardest in serum calcium once osteoclast activity is blocked.
Osteonecrosis of the Jaw and Other Toxicities Required Vigilance
Two patients developed suspected osteonecrosis of the jaw. One case occurred 10 months after denosumab began in relapsed disease; the other appeared 11 days after treatment started in newly diagnosed disease, raising concern for pre-existing dental pathology. No treatment-related deaths occurred. Other common adverse events included infection, neutropenia, fatigue, and diarrhea, but those toxicities are difficult to separate from concurrent myeloma therapy in this mixed cohort. The investigators did not identify a signal suggesting dose reduction could solve the hypocalcemia problem, because the protocol did not allow denosumab dose reductions.
The study closed early because accrual was slow, and that matters when interpreting the findings. A 22-patient analysis cannot define a standard of care. It can, however, define a risk pattern. Here, the pattern is consistent: denosumab retained antiresorptive activity in severe renal impairment, but the calcium liability was substantial even with mandated calcium, vitamin D, and baseline 25-OH vitamin D levels at or above 30 ng/mL. The safety burden remained high despite those precautions.
Severe Renal Impairment Changes the Denosumab Equation
These findings extend beyond myeloma and align with broader concerns about denosumab in advanced chronic kidney disease. Regulatory action in osteoporosis has already reflected that concern, and the same physiologic issue applies here: when kidney disease limits vitamin D activation and distorts mineral metabolism, calcium homeostasis becomes fragile. In this trial, the signal was strong enough to prompt caution but not strong enough to dismiss denosumab altogether. For patients who cannot receive bisphosphonates, the drug still offers a path to bone protection that is otherwise hard to achieve.
The unresolved issue is dose optimization. The International Myeloma Working Group bone subcommittee has already described a similar hypocalcemia burden in a larger severe renal impairment cohort and proposed monthly 60 mg dosing as a possible strategy to reduce toxicity. This phase 2 study does not test that lower dose, and it does not establish whether less frequent exposure preserves skeletal benefit while reducing calcium-related harm. What it does show is more immediate: standard denosumab dosing can suppress CTX in severe renal impairment, but the price is frequent, sometimes severe hypocalcemia that demands close biochemical monitoring, readiness to hold therapy, and rapid calcium replacement when needed.
For clinicians treating myeloma with creatinine clearance below 30 mL/min, the message is straightforward and unsentimental. Denosumab remains usable, but it is not forgiving. The next trial needs to answer whether a lower dose can preserve the antiresorptive effect without recreating the same calcium problem in a population already living close to the edge of mineral balance.